 |
|
|
| |
Efficacy and safety of long-acting subcutaneous lenacapavir
in phase 2/3 in heavily treatment-experienced people with HIV:
week 26 results (Capella study)
|
| |
| |
IAS 2021 July 18-22
J.-M. Molina * (1), S. Segal-Maurer (2), H.-J. Stellbrink (3), A. Castagna (4), M. Berhe (5), G.J. Richmond (6), P.J. Ruane (7), G.I. Sinclair (8), K. Siripassorn (9), H. Wang (10), H. Patel (10), N. Margot (10), H. Dvory-Sobol (10), R.H. Hyland (10), M.S. Rhee (10), J. Baeten (10), E. DeJesus (11) - (1) Hopital Saint Louis, Paris, France, (2) New York Presbyterian Queens, New York, United States, (3) ICH Study Center, Hamburg, Germany, (4) IRCCS Ospedale San Raffaele, Milan, Italy, (5) North Texas Infectious Diseases Consultants, Dallas, United States, (6) Gary J Richmond, MD, PA, Fort Lauderdale, United States, (7) Ruane Clinical Research Group, Los Angeles, United States, (8) PrismHealth North Texas, Dallas, United States, (9) Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand, (10) Gilead Sciences Inc., Foster City, United States, (11) Orlando Immunology Center, Orlando, United States
|
| |
|
|
|
|
|
